Developing lower-cost biosimilar antibodies using continuous manufacturing
Biosimilar development and manufacturing costs can limit access to biologic medicines. These medicines are made from living sources and cannot be copied exactly, so demonstrating biosimilarity can require substantially more evidence than developing a generic drug.
Ardent Biopharma is developing biosimilar antibodies for dermatology and oncology with manufacturing partner simAbs. It aims to use continuous manufacturing to lower production costs and make these medicines more affordable.
What stands out about Ardent Biopharma
Signed an exclusive development partnership with simAbs for two biosimilar antibodies, including GMP manufacturing activities.
Founder Ard Tijsterman co-founded Xendo, which underwent a Sovereign Capital-backed buyout in 2016.
Co-founder Menne Zaalberg served as COO of BiosanaPharma from February 2021 to June 2025 before joining Ardent.
Ard Tijsterman co-founded Tarpon Biosystems, whose BioSMB technology platform was acquired by Pall in 2015.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.